Abbott Laboratories $ABT is Hendley & Co. Inc.'s 5th Largest Position

Key Points

• Hendley & Co. Inc. has increased its stake in Abbott Laboratories by 2.6%, making it the firm's 5th largest position with a total of 107,120 shares valued at approximately $14.57 million.
• Abbott Laboratories reported earnings of $1.26 per share for the latest quarter, meeting analysts' expectations, alongside a revenue of $11.14 billion, reflecting a year-over-year growth of 7.4%.
• The company has announced a quarterly dividend of $0.59 per share, which represents an annualized dividend yield of 1.8%.

Hendley & Co. Inc. increased its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,120 shares of the healthcare product maker's stock after acquiring an additional 2,710 shares during the period. Abbott Laboratories comprises approximately 5.1% of Hendley & Co. Inc.'s portfolio, making the stock its 5th biggest holding. Hendley & Co. Inc.'s holdings in Abbott Laboratories were worth $14,569,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hughes Financial Services LLC purchased a new stake in shares of Abbott Laboratories during the first quarter worth $27,000. Abound Financial LLC acquired a new position in Abbott Laboratories during the first quarter worth $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories during the first quarter worth $30,000. JCIC Asset Management Inc. acquired a new position in Abbott Laboratories during the first quarter worth $32,000. Finally, Vision Financial Markets LLC acquired a new position in Abbott Laboratories during the first quarter worth $33,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on ABT shares. Leerink Partnrs raised shares of Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. BTIG Research lowered their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday, July 18th. Evercore ISI increased their target price on shares of Abbott Laboratories from $140.00 to $144.00 and gave the stock an "outperform" rating in a research report on Tuesday. The Goldman Sachs Group increased their target price on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a "buy" rating in a research report on Wednesday, October 1st. Finally, Mizuho raised their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and an average price target of $146.24.

Abbott Laboratories Stock Down 0.5%

ABT stock opened at $133.05 on Wednesday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a market cap of $231.58 billion, a PE ratio of 16.67, a price-to-earnings-growth ratio of 2.54 and a beta of 0.69. The business's 50-day simple moving average is $132.19 and its 200 day simple moving average is $131.45. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. During the same period last year, the business earned $1.14 earnings per share. The firm's revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is currently owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.